Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web + 0.19  Related to the article below (Last Update: 8/4/2008)


Earthtimes (press release)
Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
APAC Customer Services Announces Second Quarter 2008 Results MarketWatch
Sonic Foundry Reports Third Quarter 2008 Results IT News Online
Xantrex(TM) Technology Inc. Reports 2008 Second Quarter MarketWatch
all 865 news articles »  TSE:XTX - SOFO - APAC
Ubuntu Security Notice - devhelp, epiphany-browser, midbrowser ...
Help Net Security, Croatia -
The problem can be corrected by upgrading your system to the following package versions: Ubuntu 8.04 LTS: devhelp 0.19-1ubuntu1.8.04.3 epiphany-gecko ...
Altra Holdings Announces Record Financial Results for the Second ...
MarketWatch -
Also, the company has posted slides on its web site at http://www.altramotion.com in the Investor Relations Section in the Events & Presentations tab to ...AIMC
FMC Corporation Announces Second Quarter 2008 Results
MarketWatch - Jul 29, 2008
This event will be available live and as a replay on the web at http://www.fmc.com. Prior to the conference call, the Company will also provide supplemental ...FMC

RussiaToday
McAfee, Inc. Reports 26 Percent Growth on Record Revenue of $397 ...
MarketWatch - Jul 31, 2008
McAfee Secure Search Service, delivering one of the safest online search experiences for consumers, and McAfee SECURE(TM) for Web Sites, ...
Stratasys Reports Record Second Quarter Financial Results Trading Markets (press release)
Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased ... Trading Markets (press release)
EFI Reports Q2 2008 Results MarketWatch
all 1,219 news articles »  MFE - EFII - SSYS
Firefox 3 chipping away Safari market share, summer browsing ...
TG Daily - Aug 1, 2008
For instance, on June 1 0.19% of users were browsing the web using an iPhone. Following June 11, when the iPhone 3G was introduced, that share increased to ...

WELT ONLINE
Susquehanna Bancshares, Inc. Announces Second Quarter Results
WELT ONLINE, Germany - Jul 23, 2008
Investors will have the opportunity to listen to the conference call through a live broadcast on Susquehanna?s Web site. The event may be accessed by ...
Columbia Bancorp Releases Second Quarter Financial Results ... FOXBusiness
TriCo Bancshares Announces Quarterly Earnings MarketWatch
Cascade Bancorp (Oregon) Announces Second Quarter 2008 Net Income ... MSN Money
Primenewswire (press release) - MarketWatch
all 1,034 news articles »  SUSQ - FSGI - TCBK
Dominion Announces Second-Quarter 2008 Earnings
Earthtimes (press release), UK - Jul 31, 2008
4) Refer to schedules 2 and 3 for details related to items excluded from operating earnings, or find "GAAP Reconciliation" on Dominion's Web site at ...D
Qualcomm Announces Third Quarter Fiscal 2008 Results
FOXBusiness - Jul 23, 2008
Prior period reconciliations are presented on Qualcomm's Investor Relations web page at www.qualcomm.com. "We are pleased to report another strong quarter ...QCOM
American Medical Systems Reports Second Quarter Revenue of $129.8 ...
MarketWatch - Jul 29, 2008
A live web cast of the call will be available through the Company's corporate website at www.AmericanMedicalSystems.com and available for replay three hours ...
Samuel Manu-Tech Inc. - Second quarter results Canada NewsWire (press release)
all 30 news articles »  AMMD - TSE:SMT
Source: Google News

Web caching and Zipf-like distributions: evidence and implications -
L Breslau, P Cao, L Fan, G Phillips, S Shenker - INFOCOM'99. Eighteenth Annual Joint Conference of the IEEE …, 1999 - ieeexplore.ieee.org
... Questnet NLANR L0.04 -0.08 0.003 -0.04 -0.02 -0.09 DEC UPisa FuNet UCB Questnet
NLANR -0.19 -0.27 0.005 0.002 -0.03 -0.08 the total number of web documents, q ...

Predicting the use of web-based information systems: self-efficacy, enjoyment, learning goal … -
MY Yi, Y Hwang - International Journal of Human-Computer Studies, 2003 - Elsevier
... d. ability to use favorite Web site 0.19 0.78 0.31 0.56 0.12 0.20 0.29 3.
Enjoyment a. have fun using0.11 0.24 0.95 0.46 0.48 0.47 0.07 ...

Measuring web site quality improvements: a case study of the forum on strategic management knowledge … -
SJ Barnes, R Vidgen - Industrial Management & Data Systems, 2003 - emeraldinsight.com
... 1.63 18 Conveys a sense of community 4.35 0.19 1.51 3.67 0.22 1.70 4.59 0.24 ... 0.21
1.66 5.10 0.17 1.32 4.95 0.18 1.37 20 What is your overall view of this Web

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
Page 1. THE WORLD BANK ECONOMIC REVIEW. VOL. 6. NO. 1: 35J-J9J Measuring the
Independence of Central Banks and Its Effect on Policy Outcomes ...

Contact Sex Signals on Web and Cuticle of Tegenaria atrica (Araneae, Agelenidae) -
O Prouvost, M Trabalon, M Papke, S Schulz - Archives of Insect Biochemistry and Physiology, 1999 - doi.wiley.com
... Receptive females Unreceptive females Determination Web Cuticle Web Cuticle ... Esters
Methyl tetradecanoate (myristate) 0.19 (0.05) 0.55 (0.11)* ...

The detrital food web in a shortgrass prairie -
HW Hunt, DC Coleman, ER Ingham, RE Ingham, ET … - Biology and Fertility of Soils, 1987 - Springer
... HW Hunt et al.: The detrital food web in a shortgrass prairie ... 0.8 0.8 0.00058 0.56
0.19 0.8 0.8 0.0020 0.56 0.10 0.8 1.0 0.0020 0.56 0.10 0.5 0.8 0.021 0.56 ...

User Control and Structural Isomorphism or Disorientation and Cognitive Load?: Learning From the Web … -
WP EVELAND JR, S DUNWOODY - Communication Research, 2001 - crx.sagepub.com
... Web expertise 23.97 1 23.97 4.85 0.19 .03 .026 Cognitive load 43.48 1 43.48 8.80
?0.16 .00 .046 ... Web expertise 22.45 1 22.45 5.60 0.19 .02 .030 ...

[PDF] Removal policies in network caches for world-wide web documents -
S Williams, M Abrams, CR Strandridge, G Abdulla, E … - Computer Communication Review, 1996 - cs.kent.edu
... in networks with workloads like ours could dramat- ically reduce the load on popular
Web servers. ... Video 0.19 18.29 0.35 25.77 0.34 39.15 0.00 0.04 0.04 3.58 ...
-

Regulation of Lake Primary Productivity by Food Web Structure -
SR Carpenter, JF Kitchell, JR Hodgson, PA Cochran, … - Ecology, 1987 - JSTOR
... December 1987 LAKE PRODUCTIVITY AND FOOD WEB STRUCTURE 1869 0.6-- 0.4- 0.2- 0 6-
4- 1984 I ... SE -- 0.47, n = 13) in 1984 to 1.14 x 106/um3/mL (SE = 0.19, n = 13 ...

The development of two tools for measuring the easiness and usefulness of transactional Web sites -
AM Aladwani - European Journal of Information Systems, 2002 - ingentaconnect.com
... Table 5 Factor analysis results for Web site easiness & usefulness?holdout sample ...
Ease of finding the site 0.21 0.03 0.19 0.05 0.21 0.04 0.88 ...

Source: Google Scholar
 
 

Introgen's Novel Nanoparticle Tumor Suppressor NPRL2 Shows Promise In The Treatment Of Drug Resistant Cancers

Article Date: 21 Nov 2006 - 0:00am (PST)
Preclinical data with the NPRL2 tumor suppressor gene demonstrated that systemic treatment using NPRL2 nanoparticles in combination with cisplatin resulted in a 90 percent inhibition of tumor growth in human lung cancer cells compared to control treatments, reported Introgen Therapeutics, Inc. (Nasdaq: INGN). The NPRL2 gene, believed to be important in the genesis of multiple types of cancer, including lung cancer and renal cell cancer, is licensed to Introgen from The University of Texas M. D. Anderson Cancer Center.

This study was performed in the laboratory of Dr. Lin Ji, associate professor in the Department of Thoracic and Cardiovascular Surgery at M. D. Anderson and collaborators in the Department of Imaging Physics at M. D. Anderson and The University of Texas Southwestern Medical Center.

Article continues below and (thank you)
 
Preclinical studies evaluated the NPRL2 gene which demonstrated its ability to exhibit tumor suppressor activity against human lung cancer. A study published in a recent issue of the biomedical journal Cancer Research indicated that low expression of the NPRL2 gene may predict resistance to response to cisplatin chemotherapy in patients with lung cancer. The NPRL2 protein was analyzed in 40 lung cancers and low expression of NPRL2 was correlated with resistance to cisplatin, one of the mainstays of chemotherapy for lung cancer. In lung cancers that were resistant to cisplatin, re- introduction of the normal NPRL2 gene resulted in dramatic re-sensitization to cisplatin. This effect was confirmed in animal studies using human cisplatin- resistant lung tumors. A 90 percent inhibition of tumor growth was observed with systemic treatment using NPRL2 nanoparticles in combination with cisplatin, compared to control treatments. Thus, NPRL2 may serve as an important biomarker to identify and treat patients with tumors resistant to cisplatin chemotherapy.

These studies were further highlighted by The University of Texas M. D. Anderson Cancer Center in the November issue of their electronic publication Cancer Wise which may be accessed at http://www.cancerwise.org
 
Dr. Sunil Chada, Introgen associate vice president for Clinical Research and Development stated, "The ability to use a simple biomarker assay for NPRL2 to identify patients who would not derive benefit from cisplatin represents an important advance and underscores the significance of NPRL2 in lung cancer. Development of NPRL2 gene drugs using systemic nanoparticle delivery may help patients whose tumors are resistant to cisplatin by re-sensitizing tumors to this commonly used therapy."

NPRL2 has been identified by the International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium, including researchers from M. D. Anderson Cancer Center, The University of Texas Southwestern Medical Center, and the National Cancer Institute. The NPRL2 gene was identified within a "genomic hotspot" of cancer causing mutations at the region of the third human chromosome termed 3p21. This region is frequently deleted or mutated in early stage lung cancer. Introgen previously announced that it acquired the exclusive worldwide license for a family of at least 10 anti-cancer genes identified by the consortium including NRPL2 and FUS1. Introgen is developing INGN 401 which utilizes the FUS-1 tumor suppressor gene in a nanoparticle formulation and is now in clinical testing for the systemic treatment of metastatic non-small cell lung cancer. Additional genes within this genomic hotspot also appear to be important in control of cancer progression and may function as therapeutic genes as well as prognostic biomarkers.

Mutations in the 3p21 region of chromosome 3 are found in approximately 90 percent of small-lung cancer, more than 50 percent of non-small-lung cancer, as well as in renal, breast, pancreatic, oral and uterine cancers. Mutations in the 3p21 region of the genome are the earliest genetic abnormality currently detected in lung cancer, suggesting that one or more of these genes could act as "gatekeeper," preventing cells from becoming cancerous.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Introgen holds licensing agreements with M. D. Anderson Cancer Center to commercialize products based on licensed technologies, and has the option to license future technologies under sponsored research agreements. The University of Texas Board of Regents owns stock in Introgen. These arrangements are managed in accordance with M. D. Anderson's conflict of interest policies.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its clinical development program for treatment of cancer or other diseases with genes located in the 3p21 region of the genome, including NPRL2 and FUS-1. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Introgen Therapeutics, Inc.
http://www.introgen.com
 
Google
Web www.iconocast.com